NTHI at a glance
The past year
Chart−47.7% $4.16, close Nov 18
- From the highest close
- −61.3%
- Vs the 200-day average
- −19.2%
Short interest
History920,631 shares
- Of shares outstanding
- 3.19%
- Since the last report
- +5.0%
- Days to cover
- 7.0 days
- Settled
- Oct 30, 2026
Insider buying, 7 days
Filings$150,501 bought on the open market
- Purchases
- 1
- Form 4s filed
- Nov 13 – Nov 19
Understand the Business
Why the Stock Moved
Period-matched expectations history is not yet available. Current metrics are not a substitute for a historical explanation.
NTHI price history
Loading recent earnings…
Investment thesis
What must happen next
NTHI’s new-drug/new-delivery approach must prove clinically or commercially differentiated enough for regulators, physicians, or partners to care; otherwise there is no durable demand engine behind the company.HoldingMateriality: High
The company describes itself as formed in 2008 and devoted to developing new drugs with new delivery modes. If the delivery premise is validated, the company can become a monetizable drug-development platform; if not, the equity is mainly funding R&D with no clear buyer.
Watch: Clinical data show no meaningful safety, efficacy, or delivery advantage versus existing pharmaceutical approaches.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
The company describes itself as formed in 2008 and devoted to developing new drugs with new delivery modes.
Open source ↗Because drug development consumes cash long before commercialization, NTHI must keep access to outside capital or partner funding on non-distressed terms until its programs are validated.WeakeningMateriality: High
NTHI remains listed on Nasdaq, which can provide access to public capital markets if investors remain willing to fund the story. A funded runway preserves the option value of the pipeline; a liquidity squeeze can force dilution, asset sales, or default before the science has a chance to matter.
Watch: Biotech equity markets close to small negative-cash-flow issuers, forcing highly dilutive equity lines or convertible financing.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
NTHI remains listed on Nasdaq, which can provide access to public capital markets if investors remain willing to fund the.
Open source ↗Common shareholders only benefit if NTHI resolves its balance-sheet overhang without letting creditors, warrant holders, or new financing counterparties capture most of the drug-program upside.WeakeningMateriality: Medium
The company’s public listing gives it a mechanism to recapitalize if investor demand for the pipeline improves. Even a scientifically successful asset can be a poor common-stock outcome if the economics are transferred to new capital providers.
Watch: New secured debt, convertible notes, warrants, or equity-line financing is issued on terms that heavily dilute existing holders.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
The company’s public listing gives it a mechanism to recapitalize if investor demand for the pipeline improves.
Open source ↗Management must convert development spending into milestone progress rather than simply larger operating losses, because current operations do not generate enough revenue to self-fund the pipeline.WeakeningMateriality: Medium
Losses are consistent with a development-stage pharmaceutical company investing ahead of any meaningful commercialization. Efficient milestone creation would improve financing terms and strategic value; spending without visible progress accelerates the path to dilution or insolvency.
Watch: Trial delays, enrollment problems, or manufacturing setbacks absorb capital without moving a program toward approval or partnership.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
Losses are consistent with a development-stage pharmaceutical company investing ahead of any meaningful commercialization.
Open source ↗
Full investment case & evidence
Loading the original research archive…
Original research
NTHI’s new-drug/new-delivery approach must prove clinically or commercially differentiated enough for regulators, physicians, or partners to care; otherwise there is no durable demand engine behind the company. If the delivery premise is validated, the company can become a monetizable drug-development platform; if not, the equity is mainly funding R&D with no clear buyer.
Because drug development consumes cash long before commercialization, NTHI must keep access to outside capital or partner funding on non-distressed terms until its programs are validated. A funded runway preserves the option value of the pipeline; a liquidity squeeze can force dilution, asset sales, or default before the science has a chance to matter.
Common shareholders only benefit if NTHI resolves its balance-sheet overhang without letting creditors, warrant holders, or new financing counterparties capture most of the drug-program upside. Even a scientifically successful asset can be a poor common-stock outcome if the economics are transferred to new capital providers.
Management must convert development spending into milestone progress rather than simply larger operating losses, because current operations do not generate enough revenue to self-fund the pipeline. Efficient milestone creation would improve financing terms and strategic value; spending without visible progress accelerates the path to dilution or insolvency.
All standing thesis claims
Original report summary
NTHI is not yet a proven operating business; it is a highly levered public-market option on whether its new-drug/new-delivery programs can win external validation before liquidity and dilution overwhelm common shareholders.
Bull case and bear case
Bull case and bear case for Neonc Technologies Holdings
Where the evidence on Neonc Technologies Holdings disagrees: Mixed on the latest evidence (Nov 3, 2026). Of its 4 thesis points, 1 holding and 3 weakening.
Bull case: what the evidence supports
NTHI’s new-drug/new-delivery approach must prove clinically or commercially differentiated enough for regulators, physicians, or partners to care; otherwise there is no durable demand engine behind the company.
Bear case: what the evidence questions
Because drug development consumes cash long before commercialization, NTHI must keep access to outside capital or partner funding on non-distressed terms until its programs are validated.
Common shareholders only benefit if NTHI resolves its balance-sheet overhang without letting creditors, warrant holders, or new financing counterparties capture most of the drug-program upside.
Management must convert development spending into milestone progress rather than simply larger operating losses, because current operations do not generate enough revenue to self-fund the pipeline.
Thesis-Break Engine
Thesis-break watch · Neonc Technologies Holdings
No break has crossed Neonc Technologies Holdings’s thesis. Its break conditions are checked against every new filing as it lands.
MARKET + FINANCIAL SNAPSHOT
The numbers behind the thesis
What Changed
No assessed change was returned in this research window. That can reflect a quiet period or a coverage limit.
Risks / falsifiers
What could break the thesis
- Clinical data show no meaningful safety, efficacy, or delivery advantage versus existing pharmaceutical approaches.
- Biotech equity markets close to small negative-cash-flow issuers, forcing highly dilutive equity lines or convertible financing.
- New secured debt, convertible notes, warrants, or equity-line financing is issued on terms that heavily dilute existing holders.
- Trial delays, enrollment problems, or manufacturing setbacks absorb capital without moving a program toward approval or partnership.
NTHI news
Loading headlines…
Financial statements
NTHI income statement
Annual filed results · USD · Oldest to newest. Margins are calculated from the reported figures.
NTHI: quick answers
- When does Neonc Technologies Holdings (NTHI) report earnings next?
- Neonc Technologies Holdings's next results are projected for January 28, 2027, from the dates of its own results filings with the SEC. The company has not confirmed the date. It last reported on November 5, 2026. Earnings calendar
- What is NTHI's short interest?
- As of October 30, 2026, 920,631 NTHI shares were sold short, 3.19% of its shares outstanding, up 5.0% from the count before. At the stock's average daily volume that is 7.0 days to cover. FINRA publishes the count twice a month. NTHI short interest history

